The GLP-1 Revolution — and the Monitoring Gap
Ozempic, Wegovy, Mounjaro, Zepbound. In the space of three years, GLP-1 receptor agonists have gone from specialist diabetes drugs to the most-prescribed medications on the planet. Over 52% of doctors surveyed in 2026 said they now regularly prescribe or recommend GLP-1 medications — not just for Type 2 diabetes, but for weight loss, metabolic syndrome, and cardiovascular risk reduction.
- Semaglutide (Ozempic, Wegovy) — approved for diabetes and weight loss
- Tirzepatide (Mounjaro, Zepbound) — dual GIP/GLP-1 agonist, approved 2023
- Liraglutide (Victoza, Saxenda) — older GLP-1, once-daily injection
- Dulaglutide (Trulicity) — weekly GLP-1 injection for Type 2 diabetes
Despite the widespread use of these medications, surveys show that fewer than 40% of patients on GLP-1 drugs receive regular blood test monitoring. This guide covers every lab test that matters — before you start, during treatment, and at every annual review.
Why GLP-1 Medications Change Your Blood Test Results
GLP-1 receptor agonists do far more than suppress appetite. They directly affect the pancreas, kidneys, liver, thyroid signalling, gut absorption, and metabolic markers across the entire body. This makes comprehensive blood monitoring both necessary and clinically valuable — many patients see dramatic improvements in their labs, but a minority experience adverse effects that are only detectable through testing.
- Lower blood sugar and HbA1c — the intended primary effect
- Reduce liver fat (hepatic steatosis) — ALT and AST often improve
- Improve lipid profile — LDL, triglycerides typically fall
- Slow gastric emptying — can impair absorption of B12, iron, folate
- Cause nausea/vomiting/diarrhoea — dehydration can stress the kidneys
- Increase lipase and amylase — mild pancreatic enzyme rises are common
- Affect thyroid C-cell activity — important in rodents, relevant to monitor in humans
Baseline Blood Tests: What You Must Do Before Starting
A complete baseline panel before your first dose establishes reference points for every organ system the medication will affect. Without a baseline, you have no way to know whether a change in your results is caused by the drug, a pre-existing condition, or something else entirely. The following tests should be performed within 4 weeks of starting any GLP-1 therapy.
- HbA1c — to confirm your starting blood sugar control
- Fasting glucose — baseline metabolic marker
- Comprehensive Metabolic Panel (CMP) — covers kidney and liver function in one panel
- Lipid panel — Total Cholesterol, LDL, HDL, Triglycerides
- TSH — thyroid function, especially if personal or family history of thyroid disease
- CBC (Full Blood Count) — baseline haemoglobin, iron stores, WBC
- Lipase — baseline pancreatic enzyme, critical for detecting future pancreatitis
- Vitamin B12 — baseline before absorption changes occur
- Vitamin D and Ferritin — before nutritional deficiencies can develop
If your doctor prescribes a GLP-1 medication without requesting any blood tests first, ask for a baseline panel. This is standard of care and protects you from undetected pre-existing conditions that could be worsened by the medication.
Test 1 — HbA1c and Fasting Glucose: Tracking the Main Effect
HbA1c is the single most important lab marker for people using GLP-1 medications. It reflects your average blood glucose level over the previous 2–3 months, and it is the primary measure of whether the medication is working. For people with Type 2 diabetes, the target HbA1c on therapy is typically below 7.0%. For those using GLP-1 for weight loss without diabetes, a normal HbA1c (below 5.7%) should be maintained and confirmed every 6 months.
- HbA1c target on GLP-1 for diabetes: below 7.0% (per ADA guidelines)
- Normal HbA1c (non-diabetic): below 5.7%
- Prediabetes range: 5.7–6.4% — GLP-1 may reverse this
- Hypoglycaemia risk: rare on GLP-1 alone, more likely when combined with insulin or sulphonylureas
- Fasting glucose should fall alongside HbA1c — monitor both together
GLP-1 medications rarely cause dangerous hypoglycaemia on their own. However, if you are also taking insulin, metformin, or sulphonylureas, your combined effect on blood sugar must be monitored carefully. Report any symptoms of dizziness, sweating, or confusion to your doctor immediately.
Test 2 — Kidney Function: Creatinine, eGFR, and BUN
Kidney monitoring is one of the most important and most overlooked aspects of GLP-1 therapy. GLP-1 medications are associated with acute kidney injury (AKI) in a small but significant number of patients — not because the drug directly damages kidneys, but because the nausea, vomiting, and diarrhoea it sometimes causes lead to severe dehydration, which stresses the kidneys. Published NIH case reports and FDA post-marketing data both document this risk. The kidneys are also responsible for clearing the medication itself, meaning impaired kidney function affects drug dosing.
- Creatinine — rises when kidneys are struggling; upper normal is ~1.2 mg/dL (women), ~1.4 mg/dL (men)
- eGFR — measures filtration rate; below 60 mL/min/1.73m² = chronic kidney disease territory
- BUN (Blood Urea Nitrogen) — also rises with dehydration and kidney stress
- If creatinine rises more than 0.3 mg/dL above baseline, contact your prescriber
- If eGFR drops by more than 15 points, dose adjustment may be required
- Drink at least 2 litres of fluid daily, especially during the dose-escalation phase when GI side effects peak
Acute kidney injury on GLP-1 medications most often occurs in the first 12 weeks — the dose-escalation period. If you experience persistent vomiting or diarrhoea lasting more than 48 hours, drink oral rehydration fluid and contact your doctor. Do not wait for your next scheduled blood test.
Test 3 — Liver Function: ALT, AST, and GGT
Liver function tests are monitored for two reasons on GLP-1 therapy — safety and treatment response. Around 30–40% of people who are prescribed GLP-1 medications have non-alcoholic fatty liver disease (NAFLD) at baseline, often undiagnosed. Weight loss and improved insulin sensitivity from GLP-1 therapy typically cause liver enzymes to normalise over 6–12 months, which is clinically significant and worth documenting. On the safety side, GLP-1 medications are not approved for use in severe hepatic impairment, and any elevation of ALT or AST above three times the normal range requires clinical investigation.
- ALT (Alanine Aminotransferase) — most liver-specific enzyme; normal 7–40 U/L
- AST (Aspartate Aminotransferase) — rises with liver inflammation or muscle damage
- GGT (Gamma-Glutamyl Transferase) — elevated in fatty liver, alcohol use, bile duct issues
- Most patients see ALT and GGT fall within 6 months of starting GLP-1 therapy
- If ALT rises above 3× the upper limit of normal, discuss with your prescriber before continuing
Test 4 — Lipase: Watching for Pancreatic Stress
Pancreatitis is listed as a serious warning in the FDA prescribing information for all GLP-1 receptor agonists. The absolute risk is low — estimated at approximately 0.1–0.3% — but because pancreatitis can be life-threatening if missed, lipase monitoring is clinically important. Clinical trials of semaglutide showed a mean increase in lipase of 22% and amylase of 13% compared to placebo. These mild enzyme rises without symptoms do not mean pancreatitis — but they establish why a baseline and periodic re-testing matters.
- Lipase — the most specific marker for pancreatitis; normal range 0–160 U/L (lab-dependent)
- A rise of more than 3× the upper limit of normal, especially with abdominal pain, requires urgent evaluation
- Mild asymptomatic lipase elevations (under 3×) are common and do not require stopping treatment
- People with a personal or family history of pancreatitis should discuss this risk with their doctor before starting
- Do not start GLP-1 therapy if you have a history of severe pancreatitis
Seek emergency care immediately if you develop severe, persistent pain in the upper abdomen — especially if it radiates to the back, comes with nausea and vomiting, and starts shortly after a dose increase. These are classic signs of acute pancreatitis.
Test 5 — Full Blood Count (CBC): Checking for Anaemia
A complete blood count (CBC) is recommended at 6 and 12 months on GLP-1 therapy. The reason is nutritional: GLP-1 medications suppress appetite significantly, and some patients reduce their food intake so dramatically that deficiencies in iron, vitamin B12, and folate develop — all of which cause anaemia. A 2025 retrospective study found that 22.4% of patients on GLP-1 receptor agonists developed at least one nutritional deficiency within 12 months.
- Haemoglobin — below 12 g/dL in women and 13.5 g/dL in men signals anaemia
- MCV (Mean Corpuscular Volume) — low MCV suggests iron deficiency; high MCV suggests B12 or folate deficiency
- Ferritin — iron stores marker; below 30 ng/mL indicates iron depletion even if haemoglobin is normal
- If anaemia develops, check B12, folate, and iron panel together to identify the cause
Test 6 — Nutritional Markers: B12, Vitamin D, Iron, and Folate
This is the most underappreciated risk of GLP-1 therapy. Because the medications slow gastric emptying and significantly reduce food intake, absorption of micronutrients is impaired over time. Vitamin B12 absorption is particularly vulnerable — it requires stomach acid and intrinsic factor, both of which decline when gastric activity slows. Iron and folate deficiency follow a similar pattern. Vitamin D depletion is driven by reduced dietary fat intake, since D is a fat-soluble vitamin. Clinical guidance from Mochi Health, Labcorp, and multiple UK NHS guidelines recommends checking these markers at 6 months and 12 months of treatment.
- Vitamin B12 — target 300–900 pg/mL; below 200 pg/mL is frank deficiency
- Ferritin — iron stores; below 30 ng/mL signals depletion even before anaemia appears
- Serum Iron and TIBC — confirm iron deficiency anaemia pattern
- Folate (Serum or RBC) — low folate causes macrocytic anaemia; important in women of childbearing age
- Vitamin D (25-OH) — target 40–60 ng/mL; below 20 ng/mL is deficiency
- Albumin — protein status marker; falls with severe caloric restriction, signals malnutrition risk
If you are eating significantly less on GLP-1 therapy — which is the intended effect — consider a high-quality multivitamin with B12 and iron, plus a vitamin D supplement. Many clinicians now recommend this as standard alongside the medication, not just when deficiency appears.
Test 7 — Lipid Panel: Cholesterol Usually Improves
Unlike most of the tests in this guide, which monitor for risks, the lipid panel on GLP-1 therapy is typically monitored to document improvement. Clinical trial data for semaglutide shows average reductions in total cholesterol, LDL, and triglycerides — particularly in patients who also lose significant weight. A 6-month lipid panel captures this improvement and can be used to discuss whether lipid-lowering medication (statins) remains necessary at the same dose.
- Total Cholesterol — target below 5.0 mmol/L (200 mg/dL)
- LDL (low-density lipoprotein) — the primary cardiovascular risk marker; typically falls 5–15% on GLP-1 therapy
- HDL (high-density lipoprotein) — "good" cholesterol; often improves with weight loss
- Triglycerides — fall significantly on GLP-1 therapy, especially with dietary improvement
- Non-HDL Cholesterol — includes all atherogenic particles; a useful combined marker
Test 8 — TSH and Thyroid: Who Needs Monitoring
Thyroid monitoring on GLP-1 therapy is not required for everyone, but it is important for two specific groups. First, in rodent studies, GLP-1 receptor agonists caused thyroid C-cell tumours at high doses. Although this has not been demonstrated in humans, the FDA label carries a warning and people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) must not take these medications. Second, patients already on levothyroxine for hypothyroidism should have their TSH checked every 3–6 months during active weight loss, because changes in body weight directly affect thyroid hormone requirements.
- TSH normal range: 0.4–4.0 mIU/L
- People on levothyroxine: check TSH every 3–6 months during active weight loss phase
- Medullary thyroid carcinoma family history: absolute contraindication to GLP-1 therapy
- MEN2 syndrome: absolute contraindication to GLP-1 therapy
- All other patients: annual TSH is reasonable; not mandatory every 3 months
Tell your prescriber immediately if you notice a lump in your neck, difficulty swallowing, persistent hoarseness, or swollen lymph nodes in the neck area while on GLP-1 therapy. These can rarely be early signs of thyroid issues that require investigation.
Your GLP-1 Blood Test Schedule: Before, During, and After
The timing of blood tests on GLP-1 therapy matters as much as which tests you get. Below is the evidence-based schedule recommended by most clinical guidelines, including guidance from the American Diabetes Association (ADA), the UK NHS, and specialist weight management clinics.
- BEFORE STARTING: HbA1c, fasting glucose, CMP (kidney + liver), lipid panel, TSH, CBC, lipase, B12, Vitamin D, Ferritin
- AT 3 MONTHS: HbA1c, CMP (especially if GI side effects were significant), fasting glucose
- AT 6 MONTHS: Full repeat — HbA1c, CMP, lipid panel, CBC, lipase, B12, Vitamin D, Ferritin, Folate
- AT 12 MONTHS: Full panel above + TSH + Albumin + any markers flagged at 6 months
- ANNUALLY THEREAFTER: Same as 12-month panel, with frequency adjusted based on results and clinical picture
- ANYTIME: If you develop severe abdominal pain, persistent vomiting, dizziness, significant fatigue, or reduced urine output — get bloods immediately, do not wait for a scheduled test
You can use LabSense AI to understand any of these blood test results instantly. Enter your value, get a plain-English explanation of whether it is normal, what it means, and what questions to ask your doctor — for free, with no sign-up needed.
Results That Need Immediate Attention
Most blood test changes on GLP-1 therapy are gradual and manageable. But certain results require you to contact your prescribing doctor the same day — not at your next scheduled appointment. Knowing these thresholds in advance puts you in control of your own safety.
- Lipase more than 3× upper limit of normal with abdominal pain → Stop drug, seek urgent review
- Creatinine rise of more than 0.3 mg/dL above baseline → Same-day call to prescriber
- eGFR drop below 30 mL/min/1.73m² → Dose adjustment or cessation needed
- ALT or AST more than 3× upper limit of normal → Investigate before continuing
- HbA1c rising above 8% despite treatment → Medication adjustment needed
- Haemoglobin below 10 g/dL (severe anaemia) → Investigate and supplement immediately
- TSH below 0.1 or above 10 mIU/L (extreme values) → Thyroid review required
Frequently Asked Questions
Do I need blood tests before starting Ozempic or Wegovy?▼
Yes. A baseline panel including HbA1c, kidney function (creatinine and eGFR), liver enzymes (ALT, AST), lipid panel, CBC, and lipase should be done within 4 weeks of starting. Without a baseline, you have no reference point to detect changes caused by the medication.
How often should I get blood tests while on Ozempic?▼
Most clinical guidelines recommend blood tests at 3 months, 6 months, and 12 months after starting, then annually. If you experience significant side effects like nausea, vomiting, or abdominal pain, bloods should be taken sooner regardless of the schedule.
Can Ozempic damage your kidneys?▼
Ozempic does not directly damage kidneys, but dehydration caused by nausea, vomiting, or diarrhoea — common side effects during dose escalation — can cause acute kidney injury. FDA post-marketing data documents this risk. Staying well hydrated and monitoring creatinine and eGFR are the key protective measures.
Does Ozempic cause pancreatitis?▼
Acute pancreatitis is a listed FDA warning for all GLP-1 medications. The absolute risk is low (around 0.1–0.3%) but pancreatitis can be serious. Clinical trials show semaglutide raises lipase by about 22% on average. This mild rise without symptoms does not mean pancreatitis — but severe upper abdominal pain radiating to the back, especially after a dose increase, requires emergency evaluation.
Why does Ozempic cause vitamin B12 deficiency?▼
GLP-1 medications slow gastric emptying and reduce stomach acid production. Vitamin B12 requires stomach acid and intrinsic factor — a protein made by the stomach lining — to be absorbed. This combination can reduce B12 absorption over time, leading to deficiency in some patients. B12 levels should be checked at 6 and 12 months, and supplementation is commonly recommended.
Does Wegovy improve cholesterol and lipid levels?▼
Yes. Clinical trial data consistently shows that semaglutide (Wegovy) reduces total cholesterol, LDL, and triglycerides — particularly in patients who also lose significant body weight. HDL (good cholesterol) typically improves too. A lipid panel at 6 months documents this improvement and may allow a statin dose reduction in some patients.
Does Mounjaro (tirzepatide) require the same blood tests as Ozempic?▼
Yes, essentially the same panel applies. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. The monitoring requirements — HbA1c, kidney function, liver enzymes, lipase, CBC, nutritional markers, and lipid panel — are the same as for semaglutide. The testing schedule (3 months, 6 months, 12 months) also applies.
Can I use LabSense AI to understand my blood test results while on Ozempic?▼
Yes. LabSense AI interprets HbA1c, creatinine, eGFR, ALT, AST, lipase, haemoglobin, B12, Vitamin D, ferritin, lipid panel, TSH, and all other markers discussed in this guide. Enter your value and get an instant plain-English explanation with reference ranges — free, no sign-up required.
References & Sources
- 1FDA Prescribing Information — Ozempic (semaglutide) injection
- 2NIH/PMC — Acute Kidney Injury Associated with Semaglutide
- 3Mochi Health — What Labs Should You Monitor on GLP-1s: A Complete Biomarker Guide
- 4Labcorp OnDemand — Health Tests to Support Your GLP-1 Weight Loss Journey
- 5Healthline — Ozempic: Blood Tests, Urine Tests, Monitoring, and More
- 6PMC — The Effect of Semaglutide on Intestinal Iron Absorption
- 7American Diabetes Association — Standards of Medical Care in Diabetes 2026
Medical Advisory
Expert oversight & content review
Dr. Naeem Mahmood Ashraf
PhD Biochemistry & Biotechnology
University of Punjab, Lahore
Dr. Naeem Mahmood Ashraf is a distinguished biochemist and biotechnologist at the University of Punjab, Lahore, Pakistan. With a PhD in Biochemistry & Biotechnology and over 45 peer-reviewed publications (h-index: 10), Dr. Ashraf brings deep expertise in clinical biochemistry, genomics, and computational biology to LabSense AI. His research bridges laboratory science and patient care, ensuring all interpretations follow WHO, IFCC, and AACC international standards.
Credentials
Areas of Expertise